Member Info for roses

Nice 200k buy at full price, level 2 is starting to tick up nicely now

Thanks wildforce, so combination therapies can significantly extend both parts of the combinations patent life span through a secondary patent

Any big pharma looking to buy scib would also look at combining them into one single product, therefore renewing both patent life spans.

Agreed, so it will be down to whoever buys scancells product that will determine who gets the exclusive revenue from it during its patent life

“…..that and the fact that iSCIB1+ addresses a much bigger potential market”

Indeed, it will be available for 100% of the market, no need for screening .

Great interview,

Then next MAB deals are expected to be around 640 million for each MAB

“

· SCOPE trial surpasses its first milestone with an 82% response rate

· To our knowledge no other combination has achieved this response rate with doublet checkpoint inhibitors in unresectable metastatic melanoma”

Whoa ! Now that’s what you call a positive news release

Hilarious, you’ve only been a member for 8 days and you’ve made 76 posts already !

Very odd drop today on just £44k shares traded for the whole day !

Pretty standard stuff, not much to say !

Berm, the uk arm of SVB has been bought by HSBC and the us gov has agreed to backstop all of the deposits so it seems the worst has been contained for the time being.

Indeed, my heart skipped a beat there for a second, only to realise that everything is fine.

I suppose some will argue that there was no need to put out that RNS, but if they hadn’t, then the usual few on here will have tried to create some doubts.

C7 have you sold some, or sold out ?

Indeed, reverse takeovers in order to gain entry to NASDAQ are very common and quite often the preferred method of entry as it is a much cheaper and quicker way to gain entry.

Wigwarmer , you posted. This morning “ Some more perspective around the trial update would have been welcome - such as an expert opinion on the relevance of the 23 DTH responses”

Well we have one of the UK’s top experts giving his opinion on it which I have just posted.

Ratcliff, indeed, I was just about to mention the carefully thought out wording.

It comes across as not ‘ if it will work’ but where can we deploy it for maximum benefit.

All this talk of whether DTH is significant or not is pointless unless you are a professional in that field.

If you guys can’t work it out then why not take it from someone who is at the very top of their profession.

Taken straight from the last news release:

Prof Christian Ottensmeier, Chief Investigator, University of Liverpool commented: "The strong DTH responses in all patients and the early clinical results, particularly in the patient with advanced SCCHN, suggests that this therapeutic cancer vaccine could have significant potential. Further studies with Modi-1 monotherapy and in combination with CPIs should tell us in which settings it will have maximum benefit to patients."

Ruck, I believe the TB test is just a standard ‘prick’ or ‘scratch’ test

Interesting that the embargo on the article still hasn’t been lifted ?